Growth in Direct-to-Consumer Marketing Efforts
The company's Direct-to-Consumer marketing efforts have achieved increased XTRAC leads, resulting in more robust patient appointments volume and higher device utilization.
Elevation in Recurring Revenue
STRATA Skin Sciences reported growth in recurring revenue per device across its domestic installed base of approximately 850 devices, marking the fourth consecutive quarter of year-over-year growth.
TheraClearX Device Expansion
The installed base of TheraClearX devices in the US increased to 160 from 104, and the number of patients submitted for reimbursement in Q1 2025 showed a 138% increase over the previous year.
International Business Growth
International sales reached $2.5 million, up 8% from the previous year, with equipment sales up 13% and recurring treatments revenue up 27%.
Improved Gross Margin
Gross margin improved to 53.5% in Q1 2025 from 45.6% in the same period in 2024, driven by efficiency gains and the absence of a one-time inventory write-off.
Reduction in Operating Expenses
Total operating expenses for Q1 2025 were reduced by 5% compared to the previous year, due to reductions in engineering, product development, and selling expenses.